Lonza Group Ltd
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $528
- Today's High:
- $556.775
- Open Price:
- $531.175
- 52W Low:
- $437.0198
- 52W High:
- $669.5902
- Prev. Close:
- $543.82
- Volume:
- 900
Company Statistics
- Market Cap.:
- $39.59 billion
- Book Value:
- 139.257
- Revenue TTM:
- $6.32 billion
- Operating Margin TTM:
- 21.21%
- Gross Profit TTM:
- $2.44 billion
- Profit Margin:
- 17.93%
- Return on Assets TTM:
- 4.87%
- Return on Equity TTM:
- 11.06%
Company Profile
Lonza Group Ltd had its IPO on under the ticker symbol LZAGF.
The company operates in the Healthcare sector and Diagnostics & Research industry. Lonza Group Ltd has a staff strength of 17,896 employees.
Stock update
Shares of Lonza Group Ltd opened at $531.18 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $528 - $556.78, and closed at $532.98.
This is a -1.99% slip from the previous day's closing price.
A total volume of 900 shares were traded at the close of the day’s session.
In the last one week, shares of Lonza Group Ltd have slipped by -3.1%.
Lonza Group Ltd's Key Ratios
Lonza Group Ltd has a market cap of $39.59 billion, indicating a price to book ratio of 3.3736 and a price to sales ratio of 6.1745.
In the last 12-months Lonza Group Ltd’s revenue was $6.32 billion with a gross profit of $2.44 billion and an EBITDA of $1.86 billion. The EBITDA ratio measures Lonza Group Ltd's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Lonza Group Ltd’s operating margin was 21.21% while its return on assets stood at 4.87% with a return of equity of 11.06%.
In Q2, Lonza Group Ltd’s quarterly earnings growth was a negative -16.2% while revenue growth was a positive 3.2%.
Lonza Group Ltd’s PE and PEG Ratio
- Forward PE
- 26.3158
- Trailing PE
- 31.2046
- PEG
- 1.5223
Its diluted EPS in the last 12-months stands at $17.08 per share while it has a forward price to earnings multiple of 26.3158 and a PEG multiple of 1.5223. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Lonza Group Ltd’s profitability.
Lonza Group Ltd stock is trading at a EV to sales ratio of 6.1914 and a EV to EBITDA ratio of 32.0192. Its price to sales ratio in the trailing 12-months stood at 6.1745.
Lonza Group Ltd stock pays annual dividends of $3.5 per share, indicating a yield of 0.72% and a payout ratio of 23%.
Balance sheet and cash flow metrics
- Total Assets
- $17.67 billion
- Total Liabilities
- $2.71 billion
- Operating Cash Flow
- $-88500000.00
- Capital Expenditure
- $420.50 million
- Dividend Payout Ratio
- 23%
Lonza Group Ltd ended 2024 with $17.67 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $17.67 billion while shareholder equity stood at $10.31 billion.
Lonza Group Ltd ended 2024 with $0 in deferred long-term liabilities, $2.71 billion in other current liabilities, 74000000.00 in common stock, $9.27 billion in retained earnings and $2.89 billion in goodwill. Its cash balance stood at $1.70 billion and cash and short-term investments were $2.15 billion. The company’s total short-term debt was $449,000,000 while long-term debt stood at $2.46 billion.
Lonza Group Ltd’s total current assets stands at $5.63 billion while long-term investments were $0 and short-term investments were $450.00 million. Its net receivables were $1.53 billion compared to accounts payable of $0 and inventory worth $1.93 billion.
In 2024, Lonza Group Ltd's operating cash flow was $-88500000.00 while its capital expenditure stood at $420.50 million.
Comparatively, Lonza Group Ltd paid $0.23 in dividends in 2024.
Other key metrics
- Current Trading Price
- $532.98
- 52-Week High
- $669.5902
- 52-Week Low
- $437.0198
- Analyst Target Price
- $
Lonza Group Ltd stock is currently trading at $532.98 per share. It touched a 52-week high of $669.5902 and a 52-week low of $669.5902. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $572.37 and 200-day moving average was $577.97 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 290.4% of the company’s stock are held by insiders while 5526.9% are held by institutions.
Frequently Asked Questions About Lonza Group Ltd
Similar Industry Stocks (Diagnostics & Research)
Most Active
Top Gainers
Top Losers
About
Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. It supports customers across various aspects of design, development, and manufacturing. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies. It also offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. In addition, this segment provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. The company was incorporated in 1897 and is headquartered in Basel, Switzerland.